BEN Inks AI Deal with Ad Giant for Top-10 Pharma Client

WILMINGTON, Del. – December 29, 2025 – Brand Engagement Network (NASDAQ: BNAI), a specialized provider of business-focused generative AI, today announced a significant new partnership that marks a major stride for artificial intelligence into the highly regulated pharmaceutical industry. The company has finalized a Vendor Services Project Agreement with a leading global advertising agency to develop a proprietary AI communication solution for one of the world's top ten pharmaceutical companies.

While the identities of the powerhouse advertising agency and its pharmaceutical client remain under wraps pending the solution's formal launch, the deal underscores a growing trend of major corporations turning to specialized AI firms for safe and secure applications. The project focuses on creating a custom AI-driven engagement method for an established prescription drug, moving beyond traditional marketing into the realm of personalized, dynamic communication.

This agreement represents a critical validation of BEN's technology and strategic focus on industries where trust and data security are paramount. The initial phase of the project is set to generate $250,000 in development revenue for BEN in the fourth quarter of 2025, with the promise of a more substantial, long-term relationship through monthly recurring license fees anticipated to begin in the first quarter of 2026.

A Calculated Push into Healthcare

This latest agreement is not an isolated venture but a key component of Brand Engagement Network's deliberate expansion within the healthcare vertical. The deal is expected to provide a significant boost to the company's fourth-quarter results, highlighting the increasing appetite for its secure AI technology in both the U.S. and international markets. The move complements BEN's recent strategic initiatives, including an exclusive licensing partnership in Latin America and the formation of Skye Salud, a sovereign AI healthcare platform designed for Mexico.

These combined efforts paint a clear picture of a company methodically building a global healthcare AI footprint. By tackling the unique challenges of the pharmaceutical sector—such as stringent regulatory compliance, the need for factual accuracy, and patient privacy—BEN is positioning itself as a go-to partner for sensitive applications. The solution being developed aims to transform how a major pharmaceutical brand communicates with its stakeholders, which could include patients, caregivers, and healthcare providers.

Tyler Luck, Acting Chief Executive Officer of BEN, emphasized the company's focus on responsible AI deployment. "This agreement reflects BEN's progression in healthcare, in which our technology delivers trusted, secured, and efficient AI for pharma manufacturers, healthcare providers, and patients," he commented in the official announcement. "We are committed to creating experiences for consumers where their needs are met with accuracy, reliability, and integrity."

The Technology of Trust in a New AI Era

At the core of this partnership is the demand for generative AI that operates within a secure, controlled environment. Unlike open-ended consumer AI models that can be prone to errors or "hallucinations," BEN's platform is designed for enterprise-grade reliability. The company, headquartered in Jackson, WY, specializes in conversational AI that can be delivered through multiple modes, including text, voice, and vision via human-like AI avatars. This multi-modal capability offers a glimpse into the potential future of patient engagement.

For the pharmaceutical industry, the implications are profound. An AI-powered communication tool could offer patients 24/7 access to verified information about their prescriptions, help with adherence schedules, or answer common questions in a conversational manner, all while ensuring the information provided is strictly vetted and compliant. For healthcare providers, such a tool could serve as a reliable resource for up-to-date drug information, freeing up valuable time.

The emphasis on a "safe and secure" framework is the critical element that unlocks these possibilities. By creating a closed-loop system where the AI draws only from a verified knowledge base, BEN mitigates the risks associated with misinformation, a non-negotiable requirement for any patient-facing health tool. This focus on building a "trust layer" for AI is what differentiates specialized providers like BEN and makes them attractive to large, risk-averse industries.

Setting a Precedent for Pharma Marketing

The confidential nature of the partnership highlights the competitive stakes involved. The first movers to successfully and safely integrate generative AI into their patient communication strategies stand to gain a significant advantage. This project could set a new industry standard, moving marketing and patient support away from static websites and call centers toward interactive, personalized, and highly scalable AI-driven experiences.

The initial development work is structured across two Statements of Work, indicating a phased and meticulous approach to building and testing the solution. The subsequent transition to a recurring revenue model based on licensing fees suggests that BEN will not just be a one-time developer but an ongoing technology partner, responsible for maintaining and updating the AI platform. This long-term structure is typical for enterprise software-as-a-service (SaaS) deals and points to the confidence both the agency and its pharma client have in the viability of the solution. As BEN continues to build on its healthcare successes in the Americas, this landmark deal with a top-tier pharmaceutical company could serve as a powerful case study, paving the way for broader adoption of its technology across the entire healthcare ecosystem.